Amgen wins FDA approval for Rituxan biosimilar Riabni
Amgen has received the US Food and Drug Administration (FDA) approval for Riabni (rituximab-arrx), its biosimilar to Roche’s Rituxan (rituximab), to treat certain cancers types. The FDA approval
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XAmgen has received the US Food and Drug Administration (FDA) approval for Riabni (rituximab-arrx), its biosimilar to Roche’s Rituxan (rituximab), to treat certain cancers types. The FDA approval
Thermo Fisher Scientific has announced the expansion of its commercial and clinical manufacturing capabilities for cGMP plasmid DNA with a new manufacturing facility in Carlsbad, California. The 67,000ft2
Novartis has received the US Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for its investigational oral therapy iptacopan (LNP023) in treating paroxysmal nocturnal hemoglobinuria (PNH). The
Ellume has obtained the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its rapid, at-home Covid-19 antigen test. The test is intended for non-prescription home
Eli Lilly and Co. (Lilly) has reached a definitive agreement to acquire Prevail Therapeutics, a developer of gene therapies using precision medicine technology, for a total consideration of
Roche has received the US Food and Drug Administration (FDA) approval for Ocrevus (ocrelizumab) with a shorter two-hour infusion time to treat a type of multiple sclerosis (MS).
Abbott has expanded its Pedialyte product portfolio with four new products – Pedialyte with Immune Support, Pedialyte Sport, Pedialyte Organic and Pedialyte Electrolyte Water with Zero Sugar. Pedialyte’s
UK-based AstraZeneca has agreed to acquire US-based pharmaceutical firm Alexion for a total consideration of $39bn, to drive strategic and financial development. Under the terms of the agreement,
Novartis has secured the European Commission (EC) approval for Leqvio (inclisiran) to treat adults with hypercholesterolemia or mixed dyslipidemia. Leqvio is an advanced small interfering RNA (siRNA) that
University Hospitals Birmingham NHS Foundation Trust (UHB) has selected US-based IT service management company Ensono to design, create and manage its health data research hub for acute care,